Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

This study aimed to investigate whether n−3 fatty acid supplementation reduced cardiovascular disease (CVD) events in a novel analysis using hierarchical composite CVD outcomes based on win ratio in the VITamin D and OmegA-3 TriaL (VITAL).

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Secondary analysis.

Secondary analysis

Analyses existing study data; this paper is not automatically another independent trial.

Meta-analysis unclear · Double-blind reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This was a secondary analysis of our VITAL randomized trial, which assessed the effects of marine n−3 fatty acids (1 g/day) and vitamin D3 on incident CVD and cancer among healthy older adults (n = 25,871).

Source: Abstract.

The present study conducted a secondary analysis using data from the VITAL study, a randomized, double-blind, placebo-controlled trial with a two-by-two factorial design.

Source: Methods.

The study recruited eligible individuals from the general population in the United States, specifically targeting men aged 50 years or older and women aged 55 years or older.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes

Secondary analysis · Nutrients · 2023

Original publication title

Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes

Soshiro Ogata; JoAnn E. Manson; Jae H. Kang; Julie E. Buring; I-Min Lee; Kunihiro Nishimura; Yasuhiko Sakata; Jacqueline Suk Danik; Denise D’Agostino; Samia Mora; Christine M. Albert; Nancy R. Cook

© 2023 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

This study aimed to investigate whether n−3 fatty acid supplementation reduced cardiovascular disease (CVD) events in a novel analysis using hierarchical composite CVD outcomes based on win ratio in the VITamin D and OmegA-3 TriaL (VITAL). This was a secondary analysis of our VITAL randomized trial, which assessed the effects of marine n−3 fatty acids (1 g/day) and vitamin D3 on incident CVD and cancer among healthy older adults (n = 25,871). The primary analysis estimated win ratios of a composite of major CVD outcomes prioritized as fatal coronary heart disease, other fatal CVD including stroke, non-fatal myocardial infarction (MI), and non-fatal stroke, comparing n−3 fatty acids to placebo.

The primary result was a nonsignificant benefit of this supplementation for the prioritized primary CVD outcome (reciprocal win ratio [95% confidence interval]: 0.90 [0.78 to 1.04]), similar to the 0.92 (0.80 to 1.06) hazard ratio in our original time-to-first event analysis without outcome prioritization. Its benefits came from reducing MI (0.71 [0.57 to 0.88]) but not stroke (1.01 [0.80 to 1.28]) components. For the primary CVD outcome, participants with low fish consumption at baseline benefited (0.79 [0.65 to 0.96]) more than those with high consumption (1.05 [0.85 to 1.30]). These results are consistent with, but slightly stronger than, those without outcome prioritization.

Authors’ abstract

This study aimed to investigate whether n−3 fatty acid supplementation reduced cardiovascular disease (CVD) events in a novel analysis using hierarchical composite CVD outcomes based on win ratio in the VITamin D and OmegA-3 TriaL (VITAL). This was a secondary analysis of our VITAL randomized trial, which assessed the effects of marine n−3 fatty acids (1 g/day) and vitamin D3 on incident CVD and cancer among healthy older adults (n = 25,871). The primary analysis estimated win ratios of a composite of major CVD outcomes prioritized as fatal coronary heart disease, other fatal CVD including stroke, non-fatal myocardial infarction (MI), and non-fatal stroke, comparing n−3 fatty acids to placebo.

The primary result was a nonsignificant benefit of this supplementation for the prioritized primary CVD outcome (reciprocal win ratio [95% confidence interval]: 0.90 [0.78 to 1.04]), similar to the 0.92 (0.80 to 1.06) hazard ratio in our original time-to-first event analysis without outcome prioritization. Its benefits came from reducing MI (0.71 [0.57 to 0.88]) but not stroke (1.01 [0.80 to 1.28]) components. For the primary CVD outcome, participants with low fish consumption at baseline benefited (0.79 [0.65 to 0.96]) more than those with high consumption (1.05 [0.85 to 1.30]). These results are consistent with, but slightly stronger than, those without outcome prioritization.

Publication and source details

Original title: Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes

Soshiro Ogata; JoAnn E. Manson; Jae H. Kang; Julie E. Buring; I-Min Lee; Kunihiro Nishimura; Yasuhiko Sakata; Jacqueline Suk Danik; Denise D’Agostino; Samia Mora; Christine M. Albert; Nancy R. Cook

Nutrients · 2023

* Correspondence: s_ogata@ncvc.go.jp; Tel.: +81-6-6170-1070© 2023 by the authors.2023https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).National Cancer InstituteU01 CA138962National Heart, Lung, and Blood InstituteR01 CA138962Office of Dietary SupplementsR01AT011729National Institute of Neurological Disorders and StrokeR01HL134811National Center for Complementary and Integrative HealthHL160799NHKBIK24HL136852The National Institutes of HealthJSPS KAKENHIJP22K17821The VITAL trial was funded with grants U01 CA138962, R01 CA138962, R01AT011729, R01HL134811, and HL160799, which include support from the National Cancer Institute; National Heart, Lung, and Blood Institute (NHLBI); Office of Dietary Supplements; National Institute of Neurological Disorders and Stroke; and National Center for Complementary and Integrative Health. SM was supported with NHKBI K24HL136852. The National Institutes of Health sponsored the trial and played a collaborative role in its design and execution. The final decisions regarding data collection, management, analysis, manuscript review, and publication submission were made by the trial investigators and the trial research group. This secondary analysis was supported with the JSPS KAKENHI Grant Number JP22K17821.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T06:05:03.523285+00:00

DOI: 10.3390/nu15194235 · PMC10574231